Abstract:De novo lipogenesis and the defense against oxidative lipid damage require large amounts of cytosolic NADPH. Our group has recently found that glioblastoma (GBM) up-regulate wild-type Isocitrate dehydrogenase 1 (referred to hereafter as 'wt-IDH1 high GBM) that, through oxidative decarboxylation of isocitrate, generates large quantities of alpha-ketoglutarate and cytosolic NADPH. We demonstrated that RNAi-mediated knockdown of wt-IDH1, alone and in combination with RT, slows the growth of patient-derived HGG xenografts, while overexpression of wt-IDH1 promotes intracranial HGG growth. Here, we demonstrate that wt-IDH1 high GBM produce excess NADPH, which is a rate-limiting reductant that drives de novo fatty acid biosynthesis. Isotope tracer and liquid chromatography-based lipidomic studies indicate that wt-IDH1 supports the de novo biosynthesis of mono-unsaturated fatty acids (MUFAs), promotes the incorporation of monounsaturated, and reduces the abundance of oxidizable polyunsaturated (PUFA) phospholipids in the cell membrane. Conversely, the genetic ablation of wt-IDH1 or the pharmacologic inhibition of wt-IDH1 in tumor cells, using a brain-penetrant wt-IDH1-specific small molecule, revealed a significant increase in PUFA-containing lipid species harboring oxidized arachidonic tails. Of note, two lipid species, (PE16:0_20:4) and (PE18:0_22:4), previously reported to act as substrates for 15-lipoxygenase (15-LOX) - a key enzyme that facilitates lipid peroxidation - are enriched in tumor cells with wt-IDH1 compromise. Further, we found that the enhanced NADPH production in wt-IDH1 high GBM, together with heightened biosynthesis of carbon precursors required for glutathione biosynthesis, increased levels of reduced glutathione (GSH), activate the phospholipid peroxidase glutathione peroxidase 4 (GPX4)-driven lipid repair pathway, which scavenges PUFA-containing lipid peroxides, known executioners of ferroptosis. These findings support elevated wt-IDH1 expression, the ensuing effect on the tumor lipidome, redox homeostasis, and protection against lipid peroxidation as contributors to GBM tumor growth and therapy resistance and point to the inhibition of wt-IDH1 as a ferroptosis-inducing strategy for the treatment of GBM.

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis

Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells

Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers

Oncogenic RAS signaling suppresses ferroptosis via transcriptional upregulation of GCH1

Tmet-25. Wild-Type Idh1 Inhibits Ferroptosis In Glioblastoma

DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer

Oncometabolite 2-Hydroxyglutarate is a Competitive Inhibitor of Α-Ketoglutarate-dependent Dioxygenases

Ferroptosis in life: To be or not to be

A noncanonical function of EIF4E limits ALDH1B1 activity and increases susceptibility to ferroptosis

HIF-1a drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1

MGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells

HIF-1α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1

SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways

p53: A double-edged sword in tumor ferroptosis

Advances in ferroptosis of cancer therapy

Sensitization of cancer cells to ferroptosis coincident with cell cycle arrest

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression

Insights into the Roles of Epigenetic Modifications in Ferroptosis

Deciphering the link: ferroptosis and its role in glioma